FindTrial
Sign In

tanezumab 5 mg

BIOLOGICAL6 trials

Sponsors

Pfizer

Conditions

ArthritisChronic PainLow Back PainOsteoarthritisOsteoarthritis, HipOsteoarthritis, Knee

Phase 2

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
TerminatedNCT00994890
PfizerOsteoarthritis, Hip, Osteoarthritis, Knee
Start: 2009-11-17End: 2011-03-01Updated: 2021-05-13

Phase 3

Tanezumab In Osteoarthritis Of The Knee (2)
CompletedNCT00830063
PfizerArthritis, Osteoarthritis
Start: 2009-05-05End: 2010-08-31Updated: 2021-05-13
Tanezumab in Osteoarthritis of the Hip or Knee (2)
CompletedNCT00863304
PfizerOsteoarthritis
Start: 2009-06-09End: 2010-08-16Updated: 2021-05-17
Tanezumab In Osteoarthritis Of The Hip Or Knee
TerminatedNCT00985621
PfizerOsteoarthritis
Start: 2009-10-30End: 2011-02-04Updated: 2021-05-14
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
CompletedNCT02528188
PfizerChronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Start: 2015-07-21End: 2019-02-27Updated: 2020-01-10
Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
CompletedNCT02725411
PfizerLow Back Pain
Start: 2016-05-26End: 2019-06-11Updated: 2020-08-11

Related Papers

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis
Advances in Rheumatology2024-04-221 citations
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab
Osteoarthritis and Cartilage2023-08-2921 citations
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor
CPT Pharmacometrics & Systems Pharmacology2023-07-201 citations
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
2023-07-183 citations
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis.
2022-10-272 citations
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis.
2022-09-012 citations
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials
Current Medical Research and Opinion2022-08-186 citations
Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis.
2022-08-12
Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.
2022-07-022 citations
Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
2022-05-102 citations
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
Arthritis Research & Therapy2022-03-2924 citations
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee
The Journal of Rheumatology2022-03-0123 citations
Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
2022-02-144 citations
Tanezumab for Chronic low Back Pain: A Long-Term, Randomized, Celecoxib-Controlled Japanese Phase III Safety Study
Pain Management2021-11-179 citations
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases2020-06-01153 citations
Antibodies to watch in 2020.
2020-01-01328 citations
<p>Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip</p>
Journal of Pain Research2019-03-0148 citations
Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.
2018-01-0828 citations
Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
2014-10-0168 citations